In addition, since some driver mutations are mutually exclusive, detection of specific molecular alterations might also predict resistance to specific drugs, as suggested for KRAS mutated cancers treated with EGFR tyrosine kinase inhibitors [32], [33], [34], [35], [36]. The gene discussed is KRAS; the disease is cancer.